On September 19, 2017 Realist Pharma ("Realist" or "the Company") reported that it has entered into a collaboration and contribution agreement with the Canadian Glycomics Network ("GlycoNet") to assist in development of Realist’s glycomimetic vaccines targeting multiple cancers (Press release, realist pharma, SEP 19, 2017, View Source [SID1234532040]). In the context of this agreement, GlycoNet will provide a $250,000 financial contribution as well as key expertise for the scale-up of manufacturing of key precursors, for the subsequent GMP manufacturing of material for upcoming clinical studies. The funds will support the laboratory of Dr. H. Uri Saragovi at the Lady Davis Institute in Montréal, who will lead the development of these products. GlycoNet will receive an equity consideration for this contribution.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are indeed pleased to be collaborating with GlycoNet, an international leader in glycomics, on the development of our drug. Realist’s glycomimetic vaccines target the carbohydrate portions of well-known and widespread tumor markers, making an understanding of glycomics of signal importance to our future success," said Mark de Groot, Realist’s Chief Executive Officer. "While the initial focus of the collaboration is on the tumor marker gangliosides (TMGs) GD2 and GD3, Realist’s platform is expected to be able to address up to 20 different TMG targets in total."
"The research program developed by Realist and Dr. Saragovi at the Lady Davis Institute fits beautifully with GlycoNet’s mandate to advance glycomics for the benefit of Canadians by demonstrating the crucial role of glycomics in immuno-oncology. Realist’s novel discoveries demonstrate the relevance of glycomics for applications in human health and its potential for spurring job creation and start-up success in Canada," said Dr. Todd Lowary, GlycoNet Scientific Director. "We are extremely pleased to play a role in accelerating the commercial development of research that could lead to new cancer treatments as well as value creation in Canada."